...
首页> 外文期刊>Journal of peptide science: An official publication of the European Peptide Society >A complementary La/SSB epitope anchored to Sequential Oligopeptide Carrier regulates the anti-La/SSB response in immunized animals
【24h】

A complementary La/SSB epitope anchored to Sequential Oligopeptide Carrier regulates the anti-La/SSB response in immunized animals

机译:固定在顺序寡肽载体上的互补La / SSB表位调节免疫动物的抗La / SSB反应

获取原文
获取原文并翻译 | 示例

摘要

Complementary peptide epitopes, derived from complementary RNA sequences, have been used for suppressing the autoimmune response in experimental autoimmune diseases as myasthenia gravis, allergic neuritis and allergic encephalomyelitis. Aiming at contributing to the development of a tool that could regulate the autoantibody production against La/SSB, which is the main target of autoantibodies in Sjogren's syndrome (SS) and systemic lupus erythematosus (SLE), the complementary epitope, cpep349-364, of the minor T/major B cell epitope of La/SSB, pep349-364, was utilized for the induction of neutralizing anti-cpep349-364 antibodies in rabbit immunizations. Complementary peptides were coupled to an artificial carrier, developed in our laboratory, in order to enhance the complementary potency of cpep349-364 and its counterpart. This carrier, named Sequential Oligopeptide Carrier, SOCn formed by the repeating tripeptide Lys-Aib-Gly, adopts helical conformation, which allows the anchored peptide epitopes to preserve their initial reactivity such as molecular recognition, antigenicity/immunogenicity. Our study provides proof of evidence of specific interactions between idiotypic (Id)/anti-idiotypic (ant.i-Id) antibodies generated in immunized animals by the sense epitope (conjugate 1) of La/SSB and its complementary counterpart (conjugate 11). It was also demonstrated that the Id/anti-Id association is specifically disrupted by adding either the sense epitope (conjugate 1) or its complementary counterpart (conjugate 11). A mutual neutralization of Id/anti-Id antibodies was observed in vivo, which implies that generation of anti-Id antibodies by immunization with the complementary La/SSB epitope could scavenge the anti-La/SSB response. Copyright (c) 2008 European Peptide Society and John Wiley & Sons, Ltd.
机译:源自互补RNA序列的互补肽表位已被用于抑制实验性自身免疫性疾病如重症肌无力,过敏性神经炎和过敏性脑脊髓炎的自身免疫反应。旨在促进可调节针对La / SSB的自身抗体生产的工具的开发,La / SSB是Sjogren综合征(SS)和系统性红斑狼疮(SLE)的自身抗体的主要靶标,互补表位cpep349-364 La / SSB的次要T /主要B细胞表位pep349-364用于兔免疫接种中和性抗cpep349-364抗体的诱导。互补肽与在我们实验室中开发的人工载体偶联,以增强cpep349-364及其对应物的互补效力。该载体称为顺序寡肽载体,由重复的三肽Lys-Aib-Gly形成的SOCn,具有螺旋构象,可以使锚定的肽表位保留其初始反应性,例如分子识别,抗原性/免疫原性。我们的研究提供了La / SSB的有义抗原决定簇(共轭物1)与其互补对应物(共轭物11)在免疫动物中产生的独特型(Id)/抗独特型(ant.i-Id)抗体之间特异性相互作用的证据。 。还证明了通过添加正义表位(缀合物1)或其互补对应物(缀合物11)来特异性地破坏Id /抗Id缔合。在体内观察到Id /抗Id抗体相互中和,这意味着通过用互补的La / SSB表位免疫产生抗Id抗体可以清除抗La / SSB反应。版权所有(c)2008欧洲肽协会和John Wiley&Sons,Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号